COMP <GO>
ARQT vs LLY // PIOTROSKI F-SCORE QUALITY
Arcutis Biotherapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ARQT 4
— LLY 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: LLY
LAST: $32.07 (+0.31%) • MKT CAP: $4.02B
piotroski-score
6/9
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | 83.64% | +6.56 | ARQT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | 32.36% | -35.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | 2.30% | -2.46 | LLY | /fcf-yield <GO> |
| Operating Margin | -3.30% | 40.21% | -43.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | -4.30% | 31.90% | -36.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 45.51% | +45.79 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 9.29 | -1.51 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.3 | 77.9 | -11.54 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.51 | +0.49 | ARQT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 26.3x | -2.25 | ARQT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.02B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | LLY REV | ARQT GROSS % | LLY GROSS % | ARQT FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $65.18B | 90.2% | 83.0% | -$6.3M | $16.81B |
| FY 2024 | $196.5M | $45.04B | 90.3% | 81.3% | -$112.3M | $8.82B |
| FY 2023 | $59.6M | $34.12B | 44.0% | 79.3% | -$249.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
LLY // BETA 0.51